Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study.
Evans C, Tam J, Kingwell E, Oger J; University of British Columbia MS Clinic Neurologists, Tremlett H.
Clin Ther. 2012 Feb;34(2):341-50. Epub 2012 Jan 31.
Related citations
Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis.
Qizilbash N, Mendez I, Sanchez-de la Rosa R.
Clin Ther. 2012 Jan;34(1):159-176.e5. Review.
Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy.
Curkendall SM, Wang C, Johnson BH, Cao Z, Preblick R, Torres AM, Knappertz V, Gondek K.
Clin Ther. 2011 Jul;33(7):914-25.
Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis.
Siniscalchi A, Gallelli L, Tolotta GA, Loiacono D, De Sarro G.
Clin Ther. 2010 Nov;32(12):2030-4.
A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S, Rahimi R, Abdollahi M.
Clin Ther. 2010 Oct;32(11):1871-88. Review.
Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.
Clin Ther. 2010 Jun;32(6):1061-6.
A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
Nuijten M, Mittendorf T.
Clin Ther. 2010 Apr;32(4):717-28.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on